Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.

IF 2.8 3区 医学 Q3 ONCOLOGY
Margaret Shatara, Nicole M Brossier, Andrew Cluster, Ali Y Mian, Sonika Dahiya, Amy E Armstrong, Angela C Hirbe, David H Gutmann, Kenneth Aldape, Mohamed S Abdelbaki
{"title":"Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.","authors":"Margaret Shatara, Nicole M Brossier, Andrew Cluster, Ali Y Mian, Sonika Dahiya, Amy E Armstrong, Angela C Hirbe, David H Gutmann, Kenneth Aldape, Mohamed S Abdelbaki","doi":"10.1007/s10147-025-02793-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Central nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.</p><p><strong>Methods: </strong>The tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.</p><p><strong>Results: </strong>From January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).</p><p><strong>Conclusion: </strong>This initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1659-1669"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02793-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Central nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.

Methods: The tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.

Results: From January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).

Conclusion: This initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.

儿科神经肿瘤学的合作前沿:建立一个国际肿瘤委员会,以加强护理和全球影响。
背景:中枢神经系统肿瘤是儿童癌症相关死亡的主要原因,中低收入国家和高收入国家在诊断和治疗能力方面存在显著差异。这项研究概述了建立一个国际神经肿瘤学肿瘤委员会来解决这些差距。方法:肿瘤委员会于2021年1月由美国圣路易斯华盛顿大学和9家机构合作发起,最终扩展到25个国家的39家机构。每月的虚拟会议促进了多学科病例审查,提供诊断和管理建议。对三年来的29次会议进行了回顾性分析,并对参与者进行了一项基于网络的横断面调查,评估了他们的经历和满意度。结果:从2021年1月至2023年12月,共回顾101例病例。诊断最多的是低级别胶质瘤(23.4%)和1型和2型神经纤维瘤病(32.7%)。新诊断病例占51%,而40%涉及复发或进展性疾病,9%在持续治疗期间询问。建议主要涉及治疗策略(60.7%)。先进的诊断,如甲基化分析,在一些情况下改进诊断。该调查的回复率为35%,显示出很高的满意度,91%的人认为会议具有教育意义。障碍包括时间限制(71%)和相互冲突的承诺(27%)。结论:据我们所知,该倡议代表了最大的国际儿科神经肿瘤学肿瘤委员会。多学科讨论提高了诊断准确性,为治疗决策提供了信息,并促进了教育交流。参与者报告了对专业发展和符合机构需求的积极影响。尽管面临挑战,但本研究强调了远程医疗在弥合资源差距和改善全球结果方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信